Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease.
Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease.
At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.
Company Details
- Employees
- 33
- Founded
- -
- Address
- 630 Gateway Blvd, South San Francisco,california 94080,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://lyterian.com
- Keywords
- Biotechnology and Pharmaceuticals.
- HQ
- South San Francisco, California
Lyterian Therapeutics Questions
Lyterian Therapeutics's website is http://lyterian.com
Lyterian Therapeutics's LinkedIn profile is https://www.linkedin.com/company/lyterian
Lyterian Therapeutics has
33 employees.
View email and phone details for 33
employees at Lyterian Therapeutics.
Lyterian Therapeutics's industry is
Biotechnology Research
Lyterian Therapeutics's top competitors are
The Column Group,
Calico Life Sciences,
Lycia Therapeutics,
Nurix Therapeutics,
Vicinitas Therapeutics,
Tenvie Therapeutics,
Genentech,
Frontier Medicines,
Xaira Therapeutics,
Revolution Medicines.
Lyterian Therapeutics's categories are Biotechnology Research
Lyterian Therapeutics's founding year is 2022
